Viatris Inc. Completes Acquisition of Pacira BioSciences
Viatris Inc. has finalized its acquisition of Pacira BioSciences, Inc.
Stocks · News reference
Filed: 2026-11-17 AccNo: 0001140361-26-044354 Size: 409 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Viatris Inc. has finalized its acquisition of Pacira BioSciences, Inc.
S&P Dow Jones Indices announced that Ingram Micro Holding Corp. will replace Pacira BioSciences in the S&P SmallCap 600 index effective November 17, 2026, due to Viatris Inc.'s pending acquisition of Pacira.
RBC Capital has increased its price target for Pacira BioSciences, Inc. from $25.00 to $36.50 per share.
Pacira BioSciences announced its financial results for the third quarter of 2026, reporting $176.65 million in revenue and $0.70 in diluted earnings per share.
Viatris Inc. has officially launched a cash tender offer to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share.